Daiichi Sankyo To Join Growing Japan Market For Alzheimer's Drugs
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is set to announce it is joining leading Japanese drug makers in marketing treatments for Alzheimer's disease
|
Daiichi Sankyo is set to announce it is joining leading Japanese drug makers in marketing treatments for Alzheimer's disease. Daiichi Sankyo is set to join the pack by launching Memary (memantine), which it licensed from Germany's Merz. The drug is said to operate differently than Eisai's Aricept (donepezil), Japan's most-popular Alzheimer's disease treatment. Because Aricept and Memary can be taken together, Daiichi Sankyo plans to market its drug to patients who do not respond well to Aricept. Takeda Pharmaceutical also has a treatment, Reminyl (galantamine), which it launched with Janssen Pharmaceutical KK in March. (Click here for more - a subscription may be required) "Big Pharma Aiming For More From Alzheimer's Drugs" - Nikkei (Japan) (6/4/11) |